COMP <GO>
BIO vs LLY // FORWARD P/E MULTIPLE
Bio-Rad Laboratories Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: BIO 3
— LLY 11
▲ FORWARD P/E MULTIPLE LEADER: BIO
LAST: $384.40 (-0.19%) • MKT CAP: $10.28B
forward-pe
12.6x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIO VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIO | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.90% | 83.64% | -31.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.50% | 32.36% | -31.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 60.4x | 36.4x | +23.98 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 3.64% | 2.30% | +1.34 | BIO | /fcf-yield <GO> |
| Operating Margin | 1.80% | 40.21% | -38.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 29.40% | 31.90% | -2.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 0.70% | 45.51% | -44.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.59 | 9.29 | -5.70 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.0 | 66.6 | -7.60 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.51 | +0.53 | BIO | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 12.6x | 26.3x | -13.65 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.28B | $1.29T | -$1.28T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIO REV | LLY REV | BIO GROSS % | LLY GROSS % | BIO FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | $65.18B | 51.9% | 83.0% | $374.6M | $16.81B |
| FY 2024 | $2.57B | $45.04B | 53.7% | 81.3% | $289.6M | $8.82B |
| FY 2023 | $2.67B | $34.12B | — | 79.3% | $254.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIO // BETA 1.04
LLY // BETA 0.51